Zobrazeno 1 - 10
of 36
pro vyhledávání: ''
Publikováno v:
Pharmacological Reports
Background Intense statin therapy was found to impair testosterone production in men. Metformin administered to subjects with hypergonadotropic hypogonadism decreased gonadotropin production. The current study was aimed at investigating whether metfo
Autor:
Diana Santiago, Juan Guzmán, Julio Sandoval, Zaira Torres, Héctor González-Pacheco, Claudia Tavera-Alonso, Karen Audelo, Luis M. Amezcua-Guerra, Julieta González-Flores, Carlos García-Ávila, Francisco M. Baranda-Tovar
Publikováno v:
Inflammation Research
Objective To investigate whether a simplified inflammation-based risk scoring system comprising three readily available biomarkers (albumin, C-reactive protein, and leukocytes) may predict major adverse outcomes in patients with COVID-19. Methods Upo
Autor:
Xiaohui Wang, Karthik Venkatakrishnan, Elliot Offman, Michael J. Hanley, Neeraj Gupta, David Kerstein, Marita Prohn, Narayana I. Narasimhan
Publikováno v:
Clinical Pharmacokinetics
Background and objectives Brigatinib is an oral tyrosine kinase inhibitor approved in multiple countries for the treatment of patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer who have progressed on or are intole
Autor:
Joseph W. Chow, Angela Wardman, David Wilson, Helen Broadhurst, Paul Newell, Katrina Yates, Karen Cheng
Publikováno v:
Drug Safety
Introduction Ceftazidime–avibactam combines the established anti-pseudomonal cephalosporin, ceftazidime, with the novel non-β-lactam β-lactamase inhibitor, avibactam. Objectives The aim of this study was to evaluate the safety of ceftazidime–av
Autor:
Carol Cronenberger, Sarah Hackley, Hideto Kameda, Sebastião Cezar Radominski, Muhammad I. Rehman, Rieke Alten, Michael L. Tee, Alan Kivitz, Stanley Cohen, Oliver von Richter, Min Zhang
Publikováno v:
Biodrugs
Objective Our objective was to evaluate the long-term efficacy, safety, and immunogenicity of the infliximab biosimilar, PF-06438179/GP1111 (PF-SZ-IFX), in patients with rheumatoid arthritis (RA) who continued biosimilar treatment throughout 78 weeks
Autor:
Alexander C. Schmidt, Gael Dos Santos, Tamara Eckermann, Xavier Martínez-Gómez, Vishvesh Shende, Ignacio Salamanca de la Cueva, Lode Godderis, Hugo Loos, Bach-Yen Nguyen, Silvia Damaso, Anne Yeakey
Publikováno v:
Drug Safety
INTRODUCTION: Seasonal influenza causes numerous deaths worldwide each year. Annual vaccination for disease prevention is crucial. Seasonal vaccines are updated each year to closely match circulating strains. OBJECTIVE: To comply with European Medici
Publikováno v:
Clinical Pharmacokinetics
Risankizumab is a humanized immunoglobulin (Ig) G1 monoclonal antibody developed and approved for the treatment of moderate-to-severe plaque psoriasis at a dose of 150 mg administered subcutaneously at weeks 0 and 4, and every 12 weeks thereafter. On
Autor:
Igor Bondarenko, Maciej Bryl, Kazuo Kasahara, Vladimir Ivanovich Vladimirov, Manuela Zereu, Kostas N. Syrigos, Niels Reinmuth, Angel H. Bair, Fiona Hilton, K. F. Liau
Publikováno v:
Biodrugs
Background PF-06439535 is a bevacizumab biosimilar. We aimed to compare the efficacy and safety of PF-06439535 with that of reference bevacizumab (Avastin®) sourced from the EU (bevacizumab-EU), each with paclitaxel and carboplatin, in the first-lin
Autor:
Simon Zhou, Yan Li, Kathryn Newhall, Richard Delarue, Stephen E. Maxwell, Vitalina Komashko, Steven Novick, Justine Dell’Aringa, Myron S. Czuczman, Shelonitda Rose, Nurgul Kilavuz, C. L. Beach, Maria Palmisano, Lars Sternas, Ken Ogasawara
Publikováno v:
Clinical Pharmacokinetics
Background and Objectives Durvalumab, a human monoclonal antibody targeting programmed cell death ligand 1, has been approved for urothelial carcinoma and stage III non-small cell lung cancer by the US Food and Drug Administration and is being evalua
Autor:
Jessica B Jordan, Louis S. Matza, Kirsi Norrbacka, Kristina S. Boye, Luis-Emilio Garcia-Perez, Ren Yu, Syed Wasi Hassan, Dara Stein
Publikováno v:
Drugs in R&D
Drugs in R&D, Vol 19, Iss 2, Pp 213-225 (2019)
Drugs in R&D, Vol 19, Iss 2, Pp 213-225 (2019)
Introduction Patients with type 2 diabetes mellitus (T2DM) who fail to meet glycaemic control are at increased risk of diabetes complications. For patients who cannot maintain glycaemic control with oral medication, one recommended option is to add a